All In Biotech

Drug Trial Radar · NCT00676507

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

Phase III Study of Lucanix™ (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Lucanix™ Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy

Last checked: Nov 20, 2026Latest source record: May 8, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 532 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

532

Actual

Start

Jul 2008

Primary completion

Jan 2013

Study completion Jan 2013

Sponsor

Lead sponsor
NovaRx CorporationIndustry
Sponsor type
Industry
First posted
May 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rationale: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. It is not yet known whether vaccine therapy is more effective than a placebo as maintenance therapy in treatment of subjects with non-small cell lung cancer. Purpose: This randomized phase III trial is studying vaccine therapy to see how well it works compared with a placebo in treating subjects with stage III or stage IV non-small cell lung cancer.

Conditions

  • Lung Neoplasm
  • Carcinoma Non-small Cell Lung Cancer Stage IIIA
  • Carcinoma Non-small Cell Lung Cancer Stage IIIB
  • Carcinoma Non-small Cell Lung Cancer Stage IV

Interventions

  • Lucanix™Biological

    Treatment Arm: Subjects receive Lucanix™ (belagenpumatucel-L) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.

  • Placebo ComparatorOther

    Control Arm: Subjects receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare the overall survival of subjects with stage III or IV non-small cell lung cancer treated with belagenpumatucel-L (Lucanix™) vs placebo.Time frame: 7 years

Locations

82 sites in 8 countries. Site status is shown where the registry gives one.

  • Southern Cancer Center

    Mobile, Alabama

  • Alaska Regional Hospital

    Anchorage, Alaska

  • Mayo Clinic Cancer Center

    Scottsdale, Arizona

  • Clopton Clinic Hematology/Oncology

    Jonesboro, Arkansas

  • Comprehensive Blood and Cancer Center

    Bakersfield, California

  • University of California, San Diego

    La Jolla, California

  • UCLA Pasadena Oncology

    Pasadena, California

  • Cancer Care Associates

    Redondo, California

  • Innovative Research Center of California

    San Diego, California

  • Sansum Clinic

    Santa Barbara, California

  • Santa Barbara Hematology Oncology Medical Group, Inc.

    Santa Barbara, California

  • Central Coast Medical Oncology Corporation

    Santa Maria, California

  • UCLA Cancer Center

    Santa Monica, California

  • UCLA Cancer Center-Valencia

    Valencia, California

  • UCLA Cancer Center

    Westlake Village, California

  • University of Colorado Health Science Center

    Aurora, Colorado

  • Pasco Hernando Oncology Associates, P.A.

    Brooksville, Florida

  • Medical Specialist of Palm Beaches

    Lake Worth, Florida

  • Ocala Oncology

    Ocala, Florida

  • Space Coast Medical Center

    Titusville, Florida

  • Atlanta Cancer Care

    Roswell, Georgia

  • Kootenai Cancer Center

    Coeur d'Alene, Idaho

  • St. Francis Medical Group Oncology and Hematology Specialists

    Indianapolis, Indiana

  • Iowa Blood and Cancer Center

    Cedar Rapids, Iowa

  • James Graham Brown Cancer Center

    Louisville, Kentucky

  • Hematology Oncology Life Center

    Alexandria, Louisiana

  • National Cancer Institute Center for Cancer Research, Medical Oncology Branch

    Bethesda, Maryland

  • Henry Ford Health System

    Detroit, Michigan

  • University of Minnesota Medical Center

    Minneapolis, Minnesota

  • Mayo Clinic Cancer Center

    Rochester, Minnesota

  • University of Tennessee Cancer Institute

    Southaven, Mississippi

  • Comprehensive Cancer Centers of Nevada

    Henderson, Nevada

  • Comprehensive Cancer Centers of Nevada

    Henderson, Nevada

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • Richmond University Medical Center

    Staten Island, New York

  • Eastchester Center for Cancer Care

    The Bronx, New York

  • Allergy Partners of West North Carolina

    Asheville, North Carolina

  • Cancer Care of WNC

    Asheville, North Carolina

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.